1. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
   Caecilia H C Sukowati et al, 2021, World Journal of Stem Cells CrossRef
2. Tumor Budding Is an Independent Prognostic Factor in Pancreatic Adenocarcinoma and It Positively Correlates with PD-L1 Expression on Tumor Cells
   Rafał Pęksa et al, 2022, Biomedicines CrossRef
3. Drugless nanoparticles tune-up an array of intertwined pathways contributing to immune checkpoint signaling and metabolic reprogramming in triple-negative breast cancer
   Asmaa Ramzy et al, 2023, Biomedical Materials CrossRef
4. Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis
   Chin-Lin Guo, 2022, Frontiers in Cell and Developmental Biology CrossRef
5. A Novel Hypoxic-Angiogenesis-Immune-Related Gene Model for Prognostic and Therapeutic Effect Prediction in Hepatocellular Carcinoma Patients
   Wen Lv et al, 2022, Disease Markers CrossRef
6. Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
   Suman Kumar Ray et al, 2022, Current Drug Targets CrossRef